Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$32.24
+0.7%		$36.27
$13.78
▼
$43.73
$5.59B0.312.16 million shs641,480 shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$136.29
-2.7%		$82.36
$41.50
▼
$151.46
$6.09B3.25969,322 shs476,700 shs
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
$11.07
-3.1%		$15.93
$10.56
▼
$28.23
$1.44BN/A809,701 shs478,429 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$57.33
-2.6%		$62.42
$22.59
▼
$68.73
$5.41B1.051.99 million shs605,773 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
+1.14%+1.94%-8.51%-17.24%+122.98%
GRAIL, Inc. stock logo
GRAL
GRAIL
+2.60%+27.49%+76.54%+102.75%+136.97%
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
+3.91%-13.02%-25.84%-48.07%+1,141,999,900.00%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-1.85%-1.59%-11.16%+3.48%+146.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$32.24
+0.7%		$36.27
$13.78
▼
$43.73
$5.59B0.312.16 million shs641,480 shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$136.29
-2.7%		$82.36
$41.50
▼
$151.46
$6.09B3.25969,322 shs476,700 shs
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
$11.07
-3.1%		$15.93
$10.56
▼
$28.23
$1.44BN/A809,701 shs478,429 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$57.33
-2.6%		$62.42
$22.59
▼
$68.73
$5.41B1.051.99 million shs605,773 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
+1.14%+1.94%-8.51%-17.24%+122.98%
GRAIL, Inc. stock logo
GRAL
GRAIL
+2.60%+27.49%+76.54%+102.75%+136.97%
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
+3.91%-13.02%-25.84%-48.07%+1,141,999,900.00%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-1.85%-1.59%-11.16%+3.48%+146.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
2.75
Moderate Buy$51.5659.91% Upside
GRAIL, Inc. stock logo
GRAL
GRAIL
2.33
Hold$93.60-31.32% Downside
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
2.75
Moderate Buy$42.75286.18% Upside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.75
Moderate Buy$69.5021.22% Upside

Current Analyst Ratings Breakdown

Latest KLRA, GRAL, COGT, and TVTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/1/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$75.00 ➝ $155.00
9/28/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$80.00 ➝ $150.00
9/25/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$65.00 ➝ $100.00
9/24/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/24/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$75.00 ➝ $89.00
9/22/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$96.00 ➝ $118.00
9/22/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$76.00
9/22/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$67.00
9/18/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/17/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$84.00
9/17/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSector Perform$84.00
(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/A$3.84 per shareN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
$147.17M41.37N/AN/A$66.13 per share2.06
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
N/AN/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$490.73M11.01$0.35 per share165.66$1.28 per share44.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$328.94M-$2.16N/AN/AN/AN/A-84.47%-47.72%11/6/2026 (Estimated)
GRAIL, Inc. stock logo
GRAL
GRAIL
-$408.35M-$9.75N/AN/AN/A-236.95%-15.88%-14.02%11/11/2026 (Estimated)
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
-$148.96M-$3,651.09N/AN/AN/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$25.55M-$0.46N/A21.80N/A-7.35%-55.15%-6.88%10/29/2026 (Estimated)

Latest KLRA, GRAL, COGT, and TVTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$0.0299N/AN/AN/A$195.68 millionN/A
8/12/2026Q2 2026
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
-$0.74-$1.09-$0.35-$1.09N/AN/A
8/10/2026Q2 2026
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$0.5550-$0.52+$0.0350-$0.52$0.00 millionN/A
8/5/2026Q2 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.66-$2.56+$0.10-$2.56$42.39 million$44.69 million
8/4/2026Q2 2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.1347-$0.10+$0.0347-$0.37$157.27 million$169.58 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/AN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
0.48
13.57
13.57
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
10.95
10.95
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
N/A
11.11
11.11
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
24.58
4.05
3.99

Institutional Ownership

CompanyInstitutional Ownership
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
N/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
6.59%
GRAIL, Inc. stock logo
GRAL
GRAIL
1.83%
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
N/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.44%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
258173.52 million162.09 millionOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
91044.67 million43.85 millionOptionable
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
145129.64 millionN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
49794.26 million90.08 millionOptionable

Recent News About These Companies

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
September 30 at 9:58 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-travere-therapeutics-inc-to-contact-law-firm-302893828.html
Critical Survey: Travere Therapeutics (NASDAQ:TVTX) & Vericel (NASDAQ:VCEL)
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31054631
Travere Therapeutics (NASDAQ:TVTX) Earns "Outperform" Rating from Wedbush
September 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31042940
Travere Therapeutics (TVTX) Sets CEO Handover For December 2026
September 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/travere-therapeutics-tvtx-sets-ceo-011323451.html
Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today
September 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/travere-therapeutics-tvtx-stock-may-141323925.html
Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down - Here's Why
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-travere-therapeutics-nasdaq-tvtx-shares-gap-down-heres-why-2026-09-22/
Travere Therapeutics' (TVTX) "Outperform" Rating Reaffirmed at Wedbush
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-travere-therapeutics-tvtx-outperform-rating-reaffirmed-at-wedbush-2026-09-22/
Travere Therapeutics' (TVTX) Buy Rating Reaffirmed at HC Wainwright
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-travere-therapeutics-tvtx-buy-rating-reaffirmed-at-hc-wainwright-2026-09-22/
Travere Therapeutics, Inc. Announces CEO Changes, Effective December 1, 2026
September 21, 2026  |  marketscreener.comM
Travere Therapeutics Announces Planned Chief Executive Officer Transition
September 21, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260921057187/en/travere-therapeutics-announces-planned-chief-executive-officer-transition/
Travere Therapeutics Insider Sold Shares Worth $2,785,021, According to a Recent SEC Filing
September 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/travere-therapeutics-insider-sold-shares-074625088.html
Travere Therapeutics (NASDAQ:TVTX) CAO Sandra Calvin Sells 5,375 Shares
September 18, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-tvtx-insider-buying-and-selling-2026-09-18/
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CAO Sells $335,023.75 in Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-travere-therapeutics-nasdaq-tvtx-cao-sells-33502375-in-stock-2026-09-17/
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) EVP Sells $538,909.74 in Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-travere-therapeutics-nasdaq-tvtx-evp-sells-53890974-in-stock-2026-09-17/
Elizabeth Reed Sells 37,500 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-elizabeth-reed-sells-37500-shares-of-travere-therapeutics-nasdaq-tvtx-stock-2026-09-17/
Jula Inrig Sells 44,674 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-jula-inrig-sells-44674-shares-of-travere-therapeutics-nasdaq-tvtx-stock-2026-09-17/
Travere Therapeutics (NASDAQ:TVTX) CFO Sells $3,148,668.72 in Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-travere-therapeutics-nasdaq-tvtx-cfo-sells-314866872-in-stock-2026-09-17/
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CEO Sells $5,956,165.16 in Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-travere-therapeutics-nasdaq-tvtx-ceo-sells-595616516-in-stock-2026-09-17/
Travere Therapeutics (NASDAQ:TVTX) Insider William Rote Sells 96,198 Shares
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-travere-therapeutics-nasdaq-tvtx-insider-william-rote-sells-96198-shares-2026-09-17/
Peter Heerma Sells 102,190 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-peter-heerma-sells-102190-shares-of-travere-therapeutics-nasdaq-tvtx-stock-2026-09-17/
Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 108,493 Shares
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-travere-therapeutics-nasdaq-tvtx-ceo-eric-dube-sells-108493-shares-2026-09-17/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:COGT

$32.24 +0.22 (+0.69%)
As of 01:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

GRAIL stock logo

GRAIL NASDAQ:GRAL

$136.29 -3.83 (-2.74%)
As of 01:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Kailera Therapeutics stock logo

Kailera Therapeutics NASDAQ:KLRA

$11.07 -0.35 (-3.06%)
As of 01:21 PM Eastern

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. With our obesity-first focus, we have built a diversified pipeline of product candidates specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate that we believe offers the potential for the greatest weight loss. We are rapidly progressing four clinical-stage product candidates, leveraging multiple glucagon-like peptide-1, or GLP-1, based mechanisms of action and routes of administration. Our lead product candidate, ribupatide (also known as KAI-9531), is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide, or GIP, receptor dual agonist peptide that we believe offers the potential for the greatest weight loss compared to all obesity management medications currently marketed or in development with a tolerability profile that is class-like or better. We are expanding our ribupatide franchise by developing a once-daily oral tablet formulation, oral ribupatide, based on the same peptide as injectable ribupatide, to provide a convenient oral option with the potential for highly differentiated tolerability with compelling weight loss among oral treatments. Additionally, we are advancing a second oral product candidate, KAI-7535, a once-daily small molecule GLP-1 receptor agonist with the potential to improve on the clinical profile of existing oral treatments. Finally, we are developing KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist, that leverages an incremental mechanism to potentially deliver compelling weight loss, improved liver fat reduction and a differentiated tolerability profile. KAI-4729 is based on a different peptide than injectable ribupatide and oral ribupatide. Obesity is a chronic, complex disease characterized by the accumulation of excessive body fat, resulting in significant negative impacts on health and quality of life. The most severely impacted patient population, people with a body mass index, or BMI, of 35 kg/m2 or greater, which we refer to as a BMI of 35+, represents the fastest growing and largest segment of this population, with half of U.S. adults with obesity expected to have a BMI of 35+ by 2030. While the approvals of GLP-1-based obesity management medications have changed the landscape of obesity management, there remains a critical need for medications offering greater weight loss, especially for those living with a higher BMI. For example, in the SURMOUNT-1 Phase 3 clinical trial, the majority of patients who had a baseline BMI of 35+ and were treated with tirzepatide, the most prescribed weight loss medicine today, were still living with obesity at the end of treatment. Both physicians and patients have identified expected weight loss as a primary treatment goal, with the magnitude of weight reduction serving as a crucial driver in therapy selection. We believe that injectable treatments will remain foundational for patients needing significant weight reduction. Meanwhile, for patients with a lower BMI, lower incidences of gastrointestinal side effects may be needed to achieve optimal weight loss and treatment persistence, and we believe oral treatments can unlock adoption for those with more modest weight loss needs, while also supporting the chronic treatment journey of those living with higher BMIs. We were originally incorporated under the laws of the State of Delaware on May 8, 2024 under the name Hercules CM Newco, Inc. We changed our name to Kailera Therapeutics, Inc. on August 22, 2024. Our principal executive offices are located in Waltham, Massachusetts.

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$57.33 -1.55 (-2.63%)
As of 01:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas